This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Research article
Haploidentical Related Donor versus Matched Sibling Donor Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome Aged Over 50 Years: A Single-Center Retrospective Study.
Qifa Liu
Southern Medical University Nanfang Hospital
Corresponding Author
ORCiD: https://orcid.org/0000-0003-4015-3952
License:
This work is licensed under a CC BY 4.0 License. Read Full License
BACKGROUND Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative therapeutic option for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Increasing data supports the utility of haploidentical related donor (HID) HSCT in fit older patients and resulting in improvement of outcomes. This study compared the outcomes of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) patients age ≥50 years underwent haploidentical related donor (HID) or matched sibling donor (MSD) allogeneic hematopoietic stem cell transplantation (allo-HSCT).METHODS We retrospectively studied 38 patients with AML/MDS aged ≥50 years who underwent HID transplantation and compared their outcomes with 55 similarly aged patients who underwent MSD transplantation.RESULTS The 100-day cumulative incidence of II-IV° acute graft-versus-host disease (GVHD) were 34.2 ± 7.7% and 23.6 ± 5.7%, respectively, in HID and MSD groups (P = 0.189), and III-IV° acute GVHD were similar between two groups (5.3% and 7.3%, respectively, P=0.700). The 2-year cumulative incidence of limited and extensive chronic GVHD was not statistically different in HID and MSD groups(22.8 ± 10.8% vs. 18.2 ± 6.0% and 18.3 ± 10.4% vs. 22.1 ± 6.8%, P = 0.890 and P=0.424, respectively). The 2-year cumulative incidences of relapse (29.5±10.3% and 20.7 ±6.1%, P=0.458), 2-year overall survival (58.5±9.7% and 67.9±6.8%, P=0.373), 2-year transplant-related mortality (17.3±6.4% and 15.0±5.3%, P=0.717), 2-year progression free survival (56.8±9.7% and 64.6±7.4%, P=0.312) were similar in the two groups.CONCLUSION The present data showed similar outcomes in patients aged 50 years and older underwent HID compared to MSD at our institution.
Keywords
haploidentical related donor, elderly, matched sibling donor, acute myeloid leukemia, myelodysplastic syndrome
Figure 1
Figure 2
Figure 3
Figure 4
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 2
Posted 23 Dec, 2019
No community comments so far
No comments provided
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Learn more about our company.
This is a preprint. It has not completed peer review.
Research article
Haploidentical Related Donor versus Matched Sibling Donor Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome Aged Over 50 Years: A Single-Center Retrospective Study.
Qifa Liu
Southern Medical University Nanfang Hospital
Corresponding Author
ORCiD: https://orcid.org/0000-0003-4015-3952
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 2
Posted 23 Dec, 2019
No community comments so far
No comments provided
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
License:
This work is licensed under a CC BY 4.0 License. Read Full License
BACKGROUND Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative therapeutic option for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Increasing data supports the utility of haploidentical related donor (HID) HSCT in fit older patients and resulting in improvement of outcomes. This study compared the outcomes of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) patients age ≥50 years underwent haploidentical related donor (HID) or matched sibling donor (MSD) allogeneic hematopoietic stem cell transplantation (allo-HSCT).METHODS We retrospectively studied 38 patients with AML/MDS aged ≥50 years who underwent HID transplantation and compared their outcomes with 55 similarly aged patients who underwent MSD transplantation.RESULTS The 100-day cumulative incidence of II-IV° acute graft-versus-host disease (GVHD) were 34.2 ± 7.7% and 23.6 ± 5.7%, respectively, in HID and MSD groups (P = 0.189), and III-IV° acute GVHD were similar between two groups (5.3% and 7.3%, respectively, P=0.700). The 2-year cumulative incidence of limited and extensive chronic GVHD was not statistically different in HID and MSD groups(22.8 ± 10.8% vs. 18.2 ± 6.0% and 18.3 ± 10.4% vs. 22.1 ± 6.8%, P = 0.890 and P=0.424, respectively). The 2-year cumulative incidences of relapse (29.5±10.3% and 20.7 ±6.1%, P=0.458), 2-year overall survival (58.5±9.7% and 67.9±6.8%, P=0.373), 2-year transplant-related mortality (17.3±6.4% and 15.0±5.3%, P=0.717), 2-year progression free survival (56.8±9.7% and 64.6±7.4%, P=0.312) were similar in the two groups.CONCLUSION The present data showed similar outcomes in patients aged 50 years and older underwent HID compared to MSD at our institution.
Figure 1
Figure 2
Figure 3
Figure 4